Mission Statement
Providing our Community with Diverse Treatment Options Through Trusted Research
Company Summary
Founded in 2006, TrueBlue Clinical Research is a privately owned and operated clinical research facility, specializing and experienced in conducting multi-specialty Phase II-IV clinical trials. We have one large clinical research facility covering a large and diverse patient base. Our staff comes with over 100 years of research experience collectively and has consistently demonstrated a record of quality, integrity and reliability. Our demonstrated track record since our inception in 2006, puts TrueBlue Clinical Research at the forefront when it comes to integrity and accuracy in clinical research.
Company Timeline
2006
MOORE Clinical Research is founded by H. Joseph Cardenas
2011
MCR expands to 3 locations; Jeffrey Smyth joins executive team
2015
Successfully enrolled and completed a 525-patient, single-site Phase 3 acne vulgaris study
2018
Investigators Scott Miller, MD and Julian Melamed, MD join MCR
2019
10,000 patients enrolled milestone
2022
MCR rebrands into TrueBlue Clinical Research
(TBCR)
2024
Moving into Metabolic Disease capabilities with Shani Davis, APRN, PHD
2023
13,000 patients enrolled milestone
2026
Celebrating 20 years of patient-centered research, community trust, and advancing science together
2006
MOORE Clinical Research is founded by H Joseph Cardenas
2011
MCR expands to 3 office locations; Jeffrey Smyth joins executive team
2015
MCR successfully enrolls and completes single site 525 patient phase 3 acne vulgaris study
2018
Investigators Scott Miller MD, Julian Melamed MD and George Monlux, Jr join MCR
2019
10,000 patients enrolled milestone is achieved
2022
MCR is acquired by PHDermatology, Amy Ross, MD CEO and rebrands into TrueBlue Clinical Research
2023
13,000 patients enrolled milestone is met
2024
Moving into Neurology Capabilities with Kavita Kalidas, MD and Metabolic disease Capabilities Shani Davis, APRN, PHD
